Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge Verbrugge

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Oncoimmunology|January 27, 2017
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMarcel A Deken, Jules Gadiot, Ekaterina S Jordanova, et al.
The Journal of Infection|August 25, 2024
The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19Robert L Gottlieb, Meredith Clement, Paul Cook, et al.
Cell Reports|November 17, 2021
Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8<sup>+</sup> T cellsElisa Matas-Rico, Elselien Frijlink, Irene van der Haar Àvila, et al.
Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Oncoimmunology|January 27, 2017
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMarcel A Deken, Jules Gadiot, Ekaterina S Jordanova, et al.
The Journal of Infection|August 25, 2024
The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19Robert L Gottlieb, Meredith Clement, Paul Cook, et al.
Cell Reports|November 17, 2021
Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8<sup>+</sup> T cellsElisa Matas-Rico, Elselien Frijlink, Irene van der Haar Àvila, et al.
Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Pageof 3